CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
Published on in CHOP News
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
Published on in CHOP News
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
Published on in CHOP News
Prestigious award recognizes Dr. High’s contribution to improving children’s health through her gene therapy research, which began during her time at CHOP.
Whitehead received life-saving treatment at CHOP, under the care of Dr. Stephan Grupp, transforming the field of cancer immunotherapy.
Read morePublished on in CHOP News
Emily Whitehead, now 17, received life-saving treatment at CHOP, transforming the field of cancer immunotherapy.
Published on in CHOP News
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
Published on in CHOP News
A new study in Nature has documented the longest persistence of CAR T cell therapy to date.
Published on in CHOP News
Aberrant splicing leads to downregulation of CD22 in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies.
Published on in CHOP News
A new study involving CHOP researchers shows next-generation DNA sequencing can predict which patients with ALL treated with CAR T therapy will relapse.
Published on in CHOP News
Results from multicenter study are first to show improved production of coagulation factor VIII over prolonged period, leading to reduction or complete elimination of bleeding events.
Published on in CHOP News
CHOP researchers have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach.